<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Nuvation-Bio-Inc-Ordinary-Shares-Class-A-US67080N1019">Nuvation Bio Inc - Ordinary Shares - Class A</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/nuvation-bio-announces-pricing-of-upsized-offering-of-250-0-million-of-convertible-senior-notes-302811504.html">Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK, June 25, 2026 Nuvation Bio Inc. (&quot;Nuvation Bio&quot;) (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the pricing of its underwritten offering (the &quot;Offering&quot;) of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due in 2032 (the &quot;Notes&quot;). The aggregate principal amount of the Offerin...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Nuvation-Bio-Inc-Ordinary-Shares-Class-A-US67080N1019">Nuvation Bio Inc - Ordinary Shares - Class A</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/nuvation-bio-announces-proposed-convertible-senior-notes-offering-302810612.html">Nuvation Bio Announces Proposed Convertible Senior Notes Offering</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK, June 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. (&quot;Nuvation Bio&quot;) (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced its intent to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of Convertible Senior Notes due in 2032 (the &quot;Notes&quot;) in an underwritten offering ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Nuvation-Bio-Inc-Ordinary-Shares-Class-A-US67080N1019">Nuvation Bio Inc - Ordinary Shares - Class A</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/nuvation-bio-to-present-at-the-jefferies-global-healthcare-conference-302783463.html">Nuvation Bio to Present at the Jefferies Global Healthcare Conference</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK, May 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in a fireside chat at the Jefferies Global ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Nuvation-Bio-Inc-Ordinary-Shares-Class-A-US67080N1019">Nuvation Bio Inc - Ordinary Shares - Class A</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/nuvation-bio-to-present-new-quality-of-life-data-for-ibtrozi-taletrectinib-in-patients-with-ros1-positive-non-small-cell-lung-cancer-at-asco-2026-annual-meeting-302782377.html">Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting</a>
    </div>

      <div class="me-0 me-md-5">
        88% of TRUST-II patients reported improved or stable quality of life at first assessment, with the majority sustaining that benefit throughout treatment Cognitive function scores improved or remained stable throughout the course of treatment with IBTROZI IBTROZI provided rapid relief from burdensome symptoms, including cough and shortness of breath NEW YORK, May 27, 2026 /PRNewswire/ -- Nuvatio...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Nuvation-Bio-Inc-Ordinary-Shares-Class-A-US67080N1019">Nuvation Bio Inc - Ordinary Shares - Class A</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/nuvation-bio-to-collaborate-with-thermo-fisher-scientific-for-us-based-manufacturing-of-ibtrozi-for-ros1-positive-non-small-cell-lung-cancer-302771484.html">Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer</a>
    </div>

      <div class="me-0 me-md-5">
        Thermo Fisher Scientific, the world leader in serving science, will now manufacture drug product for Nuvation Bio in the United States Move by Nuvation Bio further ensures critical drug supply for patients and providers NEW YORK, May 13, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today a...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Nuvation-Bio-Inc-Ordinary-Shares-Class-A-US67080N1019">Nuvation Bio Inc - Ordinary Shares - Class A</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/shareholder-alert-purcell--lefkowitz-llp-announces-shareholder-investigation-of-nuvation-bio-inc-nyse-nuvb-302765701.html">SHAREHOLDER ALERT: Purcell &amp; Lefkowitz LLP Announces Shareholder Investigation of Nuvation Bio Inc. (NYSE: NUVB)</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK, May 7, 2026 /PRNewswire/ -- Purcell &amp; Lefkowitz LLP announces that it is investigating Nuvation Bio Inc. (NYSE: NUVB) on behalf of the company&#39;s shareholders. The investigation seeks to determine whether Nuvation Bio Inc.&#39;s directors breached their fiduciary duties in connection with recent corporate actions.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Nuvation-Bio-Inc-Ordinary-Shares-Class-A-US67080N1019">Nuvation Bio Inc - Ordinary Shares - Class A</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/nuvation-bio-announces-fda-acceptance-of-supplemental-new-drug-application-for-ibtrozi-taletrectinib-with-updated-duration-of-response-in-advanced-ros1-positive-non-small-cell-lung-cancer-302763329.html">Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer</a>
    </div>

      <div class="me-0 me-md-5">
        Application includes updated TRUST-I TKI-naïve median duration of response (mDOR) and median progression-free survival (mPFS) of more than 4 years, as well as TRUST-II TKI-pretreated mDOR of nearly 20 months FDA has assigned a target action date of January 4, 2027 NEW YORK, May 6, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toug...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Nuvation-Bio-Inc-Ordinary-Shares-Class-A-US67080N1019">Nuvation Bio Inc - Ordinary Shares - Class A</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/nuvation-bio-to-participate-in-upcoming-investor-conferences-302763192.html">Nuvation Bio to Participate in Upcoming Investor Conferences</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK, May 5, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats and one-on-one meetings at...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Nuvation-Bio-Inc-Ordinary-Shares-Class-A-US67080N1019/load_more?page=3">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>